U.S. markets close in 5 hours 43 minutes

  • S&P 500

    4,683.46
    -1.79 (-0.04%)
     

  • Dow 30

    36,271.22
    -48.76 (-0.13%)
     

  • Nasdaq

    15,865.68
    -20.87 (-0.13%)
     

  • Russell 2000

    2,427.97
    +0.68 (+0.03%)
     

  • Crude Oil

    83.89
    -0.26 (-0.31%)
     

  • Gold

    1,862.10
    +31.30 (+1.71%)
     

  • Silver

    25.15
    +0.83 (+3.40%)
     

  • EUR/USD

    1.1550
    -0.0047 (-0.40%)
     

  • 10-Yr Bond

    1.4970
    +0.0650 (+4.54%)
     

  • GBP/USD

    1.3505
    -0.0054 (-0.40%)
     

  • USD/JPY

    113.6720
    +0.7920 (+0.70%)
     

  • BTC-USD

    68,231.26
    +1,124.95 (+1.68%)
     

  • CMC Crypto 200

    1,682.53
    +48.84 (+2.99%)
     

  • FTSE 100

    7,320.10
    +46.06 (+0.63%)
     

  • Nikkei 225

    29,106.78
    -178.68 (-0.61%)
     
JOBS:

Weekly jobless claims came in at a new pandemic-era low

Another 267,000 Americans filed new claims last week

Global Antifungal Drugs Market Research Report Report 2021 Featuring Major Players - Dr. Reddy's Laboratories, Merck & Co, Sanofi, Pfizer, Bayer and Perrigo Co

Research and Markets
·5 min read

Dublin, Nov. 10, 2021 (GLOBE NEWSWIRE) -- The "Antifungal Drugs: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global market for antifungal drugs, as defined in the market segmentation described and divided into prescription and over-the-counter (OTC) medications, was valued at $13.9 billion in 2020.

The value of the global market increased to an estimated $14.5 billion by 2021 and by the end of the forecast period is predicted to reach $17.9 billion, growing at a compound annual growth rate (CAGR) of 4.4%.

This report covers approved human therapeutics, with a heavy focus on therapeutics in early development. In the last five years, there has been a decrease in the number of patent applications filed in this area. Between 1990 and 1999, there were six U.S. patents granted - evidence of the evolution of drug resistance and an increased mortality rate.

These new molecular and biological entities are from traditional pharmaceutical sources, naturally derived synthetic chemicals and biological sources, as well as the "herbal natural folk medicine" marketplace. If an approved or well-known medicine is being studied in combination with another molecular entity, it is considered a new therapy and often has been included for review. New drug and patent applications are presented as the study focuses on new methods of drug administration, drug clinical trials, and discovery and development.

It should be noted that there is a strong emphasis on early research due to the critical need for new and more effective medicines; hence, the publisher is including a section of medicines intended for human utilization that are in clinical testing, as well as information on new and novel in vitro therapies. More than 98% of medicines at the preclinical level are terminated prior to their utilization in humans, and the research in this area is vast.

The report is limiting this research to therapies that depict a positive result or that represent a rare and novel approach worthy of further review from R&D groups.

The aim of this report is to initially conduct a review of the antifungal drugs currently available; explore the issues facing the use of antifungal drugs; and review some of the latest developments of new and innovative antifungal drugs, their technologies, and their intended clinical applications.

The key objective is also to conduct and provide an analysis of the market value, growth rates, market shares and market development, and examine the market dynamics and market factors influencing the growth and development of this market.

This report also looks at the challenges and potential threats facing the industry and the factors influencing the market shares of the major market suppliers as well as smaller manufacturers in local markets.

The Report Includes

  • Analyses of the global market trends, with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026

  • Highlights of key market dynamics (DROs) for antifungal drugs, regulatory scenario, and COVID-19 impact on the progress of this market

  • Comparative study of the two primary segments of antifungal medications - prescription antifungal drugs and over the counter (OTC) antifungal drugs - and issues facing the use of these products

  • Review of antifungal agents and their classification based on the mechanism of action, approved therapeutic products and relevant patents with their expiration dates

  • Information pertaining to R&D efforts, breakthrough therapy innovations, clinical trials of novel drug developments, their technologies and intended clinical applications

  • Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis

  • Descriptive company profiles of the major market players, including Dr. Reddy's Laboratories, Merck & Co., Inc., Sanofi S.A., Pfizer Inc., Bayer AG and Perrigo Company PLC

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics

  • Market Dynamics

  • Market Drivers

  • Market Restraints

Chapter 4 Introduction to Fungi and the Antifungal Drug Market

  • Introduction to Fungi

  • Classification of Fungi

  • Chytridiomycota

  • Blastocladiomycota

  • Neocallimastigomycota

  • Microsporidia

  • Ascomycota (Sac Fungi)

  • Basidiomycota (Club Fungi)

  • Glomeromycota

  • Scope of Application: Human Healthcare

  • Types and Descriptions of Fungi Diseases in Humans

  • Aspergillosis

  • Blastomycosis

  • Candidiasis

  • Coccidioidomycosis (Valley Fever)

  • Coccidioidomycosis (Cryptococcosis)

  • Dermatophytosis

  • Fungal Infections of the Eye

  • Histoplasmosis

  • Onychomycosis (Fungal Nail Infections)

  • Mucormycosis (Zygomycosis)

  • Mycetoma

  • Paracoccidioidomycosis

  • Pneumocystis Pneumonia

  • Pseudallescheriasis

  • Sporotrichosis

  • Rare Fungal Infections and Disorders

  • Risk Factors Associated with Human Fungal Infections

  • Use of Antibiotics

  • Use of Corticosteroids

  • Specific Medical Conditions

  • Central Line-Associated Bloodstream Infections

  • Surgery

  • Organ Transplantation

  • Environmental Factors

  • Hereditary Factors

  • Hospitalization

Chapter 5 Common Environmental Fungi

  • Molds and the Human Issues Associated with Them

  • Why Environmental Mold is a Unique Problem

  • Health Risks Due to Environmental Fungi and Mold

  • Environmental Molds

  • Alternaria

  • Aspergillus

  • Cladosporium

  • Penicillium

  • Eurotium

  • Rhizopus

  • Mucor

  • Geotrichum

  • Fusarium

  • Stachybotrys

  • Wallemia

  • Trichothecium

  • Scopulariopsis Brevicaulis

  • Scytalidium Dimidiatum

  • Trichoderma

  • Paecilomyces Variotii

Chapter 6 Review of Antifungal Agents

  • Introduction to Antifungal Agents

  • Classification of Antifungal Agents

  • Systemic Antifungal Drugs

  • Polyene Antibiotics

  • Azole Antifungals

  • Echinocandins

  • Antimetabolite: Flucytosine (5-FC)

  • Other Systemic Antifungal Agents

  • Topical Antifungal Drugs

  • Topical Polyene Antibiotics

  • Azoles-Imidazole

  • Others

  • Naturally Occurring Alternatives

Chapter 7 New and Innovative Antifungals: Current Developments, Clinical Trials and Product Pipelines

  • The Need for New and Innovative Antifungals

  • Strategic Approach to the Development of New Antifungal Agents

  • Identification of Bioactive Compounds

  • Nanostructured Antifungals

  • Drug Repositioning

  • Vaccine Development Against Fungal Diseases

  • Artificial Intelligence-Based Platform Technology (FungalAi)

  • Emerging Targets and Molecular Scaffolds

  • New Antifungal Drugs in Development

  • Most Notable Antifungal Compounds

  • Specific Company Product Pipelines

  • Mycovia Pharmaceuticals

  • Amplyx Pharmaceuticals

  • F2G

  • NovaBiotics Ltd.

  • Appili Therapeutics Inc.

  • Scynexis Inc.

  • Bright Angel Therapeutics

  • Valley Fever Solutions

Chapter 8 Global Market for Antifungal Medications

  • Introduction

  • Market Revenue Analysis

  • Global Market Revenue Analysis

  • Regional Overview

  • Major Developments and Trends in Antifungal Drug Treatment and Technologies

  • Prescription Antifungal Drugs

  • OTC Antifungal Drugs

  • Market Share Analysis

Company Profiles

  • Astellas Pharma Inc.

  • Bausch Health Companies Inc.

  • Bayer Ag

  • Dr. Reddy'S Laboratories Ltd.

  • Galderma Pharma S.A.

  • Gilead Sciences Inc.

  • Glenmark Pharmaceuticals Ltd.

  • Janssen Pharmaceuticals Inc. (Johnson & Johnson)

  • Leadiant Biosciences Inc.

  • Lupin

  • Merck & Co., Inc.

  • Merz Pharma Gmbh & Co. Kgaa

  • Moberg Pharma Ab

  • Mylan (Viatris)

  • Perrigo Company Plc

  • Pfizer Inc.

  • Prestige Consumer Healthcare Inc.

  • Sanofi S.A.

  • Taro Pharmaceutical Industries Ltd.

  • Teva Pharmaceuticals Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/8yl4w4

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Recommended Stories

  • Does Ocugen Have a Shot at Winning EUA for Its COVID Vaccine in Kids?

    Until late 2020, Ocugen (NASDAQ: OCGN) was an under-the-radar biotech company focusing on developing gene therapies targeting eye disease. Then along came Bharat Biotech. Bharat wanted a partner to help get Covaxin into the U.S. market.

  • Valneva shares soar on EU deal for COVID-19 vaccine

    PARIS (Reuters) -French vaccines company Valneva's share price jumped more than 20% on Wednesday after it won European Commission approval for a deal under which it would supply up to 60 million doses of its COVID-19 vaccine candidate over two years. The eighth such deal by the European Union's executive body in the fight against rising infections is a welcome boost for Valneva as it negotiates what has been a bumpy road for its COVID-19 vaccine. "The Valneva vaccine adds another option to our broad portfolio, once it is proven to be safe and effective by the European Medicines Agency (EMA)," EU health commissioner Stella Kyriakides said.

  • Could Pfizer's COVID Pill Be Even Bigger Than Its Vaccine?

    Pfizer (NYSE: PFE) has won the title of leader when it comes to coronavirus vaccine prevention. Now, Pfizer may be about to claim leadership in another blockbuster area: coronavirus treatment. Data were so strong that an independent monitoring committee recommended Pfizer stop enrolling patients in the trial -- and seek regulatory authorization.

  • 3 Ultra-High-Yield Dividend Stocks With 42% to 50% Upside, According to Wall Street

    Since the Great Recession ended more than 12 years ago, growth stocks have been the talk of Wall Street. Historically low lending rates and an accommodative Federal Reserve have paved the way for fast-paced companies to borrow cheaply in order to hire, acquire, and innovate. A report from J.P. Morgan Asset Management, a division of JPMorgan Chase, found the average annual return for companies that initiated and grew their payouts between 1972 and 2012 completely trounced the average annual return of companies that didn't pay a dividend over the same four-decade span (9.5% vs. 1.6%).

  • Moderna Stock: Bull vs. Bear

    The good news is that shares of the messenger RNA (mRNA) vaccine maker have skyrocketed over 1,100% since the beginning of 2020. The bad news is that Moderna has given up a lot of its gains with the stock plunging close to 50% below its high from earlier this year. Two Motley Fool contributors have different takes on Moderna.

  • fuboTV's Fumble This Earnings Season Shouldn't Be a Change of Possession

    It was another "beat and raise" quarterly performance for fuboTV (NYSE: FUBO) on Tuesday afternoon, even if the market reaction isn't as enthusiastic as the headline numbers would indicate. The live TV streaming service is growing its audience of sports fan at a brisk pace, and since the end of the quarter it managed to cross the symbolic mark of a million subscribers. There's no denying that fuboTV was growing at a blistering pace that would ultimately be unsustainable.

  • 2 Stocks to Pounce on During a Market Crash

    One option is to research great companies that happen to be trading at expensive valuations now and wait for a market crash to buy in on them. If a market crash does occur, any investor should pounce on shares of Square (NYSE: SQ) and Upstart (NASDAQ: UPST). Square stock has been an amazing performer over the past five years, gaining almost 2,000% in share price value.

  • Theranos lab chief says Elizabeth Holmes offered ‘implausible’ explanation for odd findings

    Kingshuk Das testifies that former CEO was resistant to critiques of company’s devices Elizabeth Holmes with her mother, Noel Holmes, during her trial in San Jose last month. Photograph: Brittany Hosea-Small/Reuters The former lab director of Theranos has testified that Elizabeth Holmes gave “implausible” excuses for apparent failures in the company’s tests and personally pushed back against his concerns about its signature blood testing machines. Kingshuk Das testified on Tuesday in the high-pr

  • Sundial Growers' CEO Has a Warning for the U.S. Pot Market

    The U.S. pot market remains illegal at the federal level, despite dozens of states passing legislation to permit it for either medical or recreational use. Full legalization could still be years away. Canada legalized marijuana more than three years ago on Oct. 17, 2018, and companies there still struggle with profitability.

  • Coinbase misses on Q3 earnings and active users, bitcoin continues historic rise

    Yahoo Finance Live's hosts break down the decline of Coinbase's active users and earnings in Q3 while bitcoin continues its surge past $68,000.

  • Cassava: A Controversial Top Pick

    This afternoon (Tuesday, Nov 9), the Clinical Trials on Alzheimer's Disease (CTAD) conference will kick off in Boston. Cassava Sciences (SAVA) will be among those making presentations over the next few days with a poster titled, “Interim Results of an Open-label Study of Simufilam in Mild-to-Moderate Alzheimer’s Disease.” B. Riley analyst Mayank Mamtani expects the presentation to include a more rounded update of the topline 12-month cognition efficacy data released toward the end of Q3. Recall,

  • Palantir is starting to show ‘cracks,’ analyst says in downgrade

    Shares of Palantir Technologies look on track to extend their slide Wednesday after RBC Capital Markets analyst Rishi Jaluria downgraded the stock, warning of "cracks emerging in the story."

  • UPS Silences the Doubters

    It's fair to say that investors approached UPS (NYSE: UPS) third-quarter earnings with a sense of trepidation. After all, its main rival FedEx (NYSE: FDX) gave a horrible earnings report in September, taking a $450 million hit due to constrained labor markets caused by the lingering impact of the COVID-19 pandemic.

  • General Electric's Breakup Should Help GE Stock

    Over the past decade, General Electric (NYSE: GE) has gradually simplified its operations, selling or spinning off a slew of non-core businesses. Here's why that could unlock big gains for GE stock over the next few years. Back in June 2018, General Electric announced that it would sell a roughly 20% stake in its healthcare business via an initial public offering (IPO), while spinning off the rest to GE shareholders.

  • Nvidia’s stock is at a stratospheric high — these five catalysts could propel it higher

    Autonomous vehicles and virtual reality are just two segments in which Nvidia will play a larger role.

  • AMC's Positive Financial Results Aren't Enough to Offset the Insanity

    AMC unveiled a surprisingly positive earnings report, but its share price decline on Tuesday wasn't surprising at all.

  • PayPal down after its Venmo-Amazon partnership, Palantir sales force expansion

    Yahoo Finance Live anchors break down earnings reports for PayPal, which took a dip after announcing its Venmo partnership with Amazon, as Palantir Technology is expected to have a strong 2022 after exceptional growth in its staffing.

  • 2 “Strong Buy” Dividend Stocks With 8% Dividend Yield

    Let’s talk about rising markets, and whether or not to buy in. That’s the question that investors need to consider right now, as the major indexes have hit record highs – but the economy is flashing signs of concern for those who care to look. Inflation continues to rise, and the 10-year Treasury bond yield, which had risen above 1.5%, has slipped to 1.4% and is trending down. Investors are seeking returns, and so are drawn to the stock markets; they’re banking that central banks will keep inter

  • Why SmileDirectClub Plummeted by 21% on Tuesday

    Tuesday was like a bad visit to the orthodontist for SmileDirectClub (NASDAQ: SDC). The teeth alignment specialist unveiled its latest set of quarterly figures, and investors found the numbers to be downright ugly. While not every number in SmileDirectClub's Q3 report was discouraging, the most notable line items were not impressive.

  • How GE's Larry Culp split the empire Jack Welch built

    When Larry Culp, the first GE chief executive not to rise from within its ranks, convened a board meeting earlier this month to greenlight the split of the industrial conglomerate into three companies, he secured its backing. It was a far cry from board meetings held in the 1980s and 1990s by one of Culp's predecessors, Jack Welch. The iconic entrepreneur got the GE board to back his moves in the opposite direction, getting GE into businesses as diverse as mortgages, credit cards and television entertainment and prompting the Federal Reserve to characterize the company as too big to fail.